Dimanche, 20 Septembre 2020
Dernières nouvelles
Principale » The Insider Buying: Huntsman Co. (HUN) CEO Acquires 10000 Shares of Stock

The Insider Buying: Huntsman Co. (HUN) CEO Acquires 10000 Shares of Stock

15 Juin 2017

The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. More interesting news about Huntsman Corporation (NYSE:HUN) were released by: Prnewswire.com and their article: "Huntsman Scheduled to Present at the VRP Materials Conference" published on June 13, 2017 as well as Seekingalpha.com's news article titled: "Huntsman Clariant Tie-Up To Unlock More Shareholder Value" with publication date: May 26, 2017. The company's Market capitalization is $5.91 Billion with the total Outstanding Shares of 239.75 million. Shell Asset has invested 0.05% in Huntsman Corporation (NYSE:HUN). It was reported on Jun, 15 by Barchart.com. Gerrard Ronald W also sold $580,986 worth of Huntsman Corporation (NYSE:HUN) on Tuesday, January 24. RARE was included in 2 notes of analysts from November 14, 2016. Goldman Sachs downgraded the shares of HUN in report on Monday, December 12 to "Neutral" rating.

About 32,894 shares traded. It has underperformed by 23.19% the S&P500. Voloridge Investment Limited Liability Corp has 249,910 shares for 0.1% of their portfolio. Following the completion of the acquisition, the chief executive officer now owns 4,042,720 shares of the company's stock, valued at approximately $96,338,017.60.

Lapides Asset Management Llc decreased its stake in Huntsman Corp (HUN) by 28.59% based on its latest 2016Q4 regulatory filing with the SEC. Financial Ser reported 59 shares stake.

Last time, the company shocked Wall Street by reporting EPS of $0.57, smashing the consensus of $0.37 per share. HUN's profit will be $162.58M for 8.76 P/E if the $0.68 EPS becomes a reality. From the opening price, the stock has seen a change of 0.06% recently clocking in with a price of $34.56.

Breast cancer 'wonder drug' to become available on the NHS
A new deal on breast cancer drug #Kadcyla means we can now recommend it for routine funding on the NHS. HER2 is a protein that makes breast cancer cells grow and can make breast cancer more aggressive.

Huntsman Corporation is a manufacturer of differentiated organic chemical products and of inorganic chemical products. It has a market cap of $5.79 Billion. The Company operates all of its businesses through its subsidiary, Huntsman International LLC (Huntsman International). The Company operates through five segments: Polyurethanes, Performance Products, Advanced Materials, Textile Effects, and Pigments and Additives. The current consensus recommendation provided by covering analysts is 2.30. Therefore 71% are positive. According to these analysts, the Low Revenue Estimate for Huntsman Corporation is 2.51 Billion and the High Revenue Estimate is 2.71 Billion. Nomura has "Buy" rating and $30 target. Kbc Gp Nv invested 0% in Huntsman Corporation (NYSE:HUN). Goldman had a markedly different take on 12/12/2016, proposing that Huntsman Corporation is now considered Neutral versus prior Buy rating. The rating was maintained by Macquarie Research on Tuesday, September 29 with "Outperform". Jefferies Group LLC cut their target price on Huntsman Corporation from $29.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 22nd. The company's stock has a normal trading capacity of 4.59M shares while the relative volume is 1.17.

More notable recent Huntsman Corporation (NYSE:HUN) news were published by: Nasdaq.com which released: "Why Huntsman Corporation (HUN) Might Be a Diamond in the Rough" on May 26, 2017, also Zacks.com with their article: "Why Huntsman Corporation (HUN) Stock Might be a Great Pick" published on May 22, 2017, Natlawreview.com published: "Upcoming/New CFIUS Filing: Clariant Ltd. and Huntsman Corporation" on May 25, 2017. On Thursday, October 15 the stock rating was maintained by KeyBanc Capital Markets with "Overweight". The firm earned "Buy" rating on Tuesday, May 30 by Jefferies.

Investors of record on Thursday, June 15th will be given a dividend of $0.125 per share. Its down 0.43, from 1.1 in 2016Q3. 39 funds opened positions while 73 raised stakes. 162.28 million shares or 1.01% less from 163.94 million shares in 2016Q3 were reported. Lpl Fin Lc has 0.01% invested in Huntsman Corporation (NYSE:HUN). The stock remained 2.46% unpredictable for the week and 3.14% for the month. Private Savings Bank & Communications holds 20,052 shares or 0.06% of its portfolio. Winfield Associate invested in 60 shares or 0% of the stock. This Beta value of Huntsman Corporation (HUN) shows that it has historically moved 283% for every 100% move in the benchmark. Shares of SS&C Technologies Holdings, Inc. Hutchin Hill Capital Lp holds 0.19% or 289,500 shares in its portfolio. The lowest 12-month price target for the shares is $21.00, which would be decrease of about -12% of its current value. Axa reported 221,100 shares.

The share price of the company (NYSE:HUN) was up +1.43%, with a high of 24.37 during the day and the volume of Huntsman Corporation shares traded was 6229377. Inc. boosted its position in shares of Huntsman Corporation by 3.4% in the first quarter. Tower Research Llc (Trc), a New York-based fund reported 510 shares.